Metabolic Learning in the Intestine: Adaptation to Nutrition and Luminal Factors

Abstract

There is increasing evidence that the magnitude and potential of intestinal nutrient absorption (sugars, fatty acids, cholesterol and triglycerides) and intestinal defense function are regulated by metabolic learning phenomena, and are influenced by dietary energy content and exercise. Metabolic overload syndromes, mainly obesity, and chronic malabsorption disorders such as inflammatory bowel disease and celiac disease have been defined as extreme phenotypes. Metabolic learning processes depend on developmental and transcriptional control systems of intestinal epithelial cell differentiation. The physiological differentiation zone of enterocytes is linked to the beta-catenin system, apolipoprotein apoA-IV and the master transcription factors Cdx2, HNF1α, and GATA4. In addition to these developmental regulatory transcription factors, nuclear receptors including RXR, LXR, PPAR, PXR, and CAR have been implicated in the generation of more absorptive enterocytes with a more differentiated phenotype on the one hand, and dedifferentiated cells with reduced capacity of detoxification and defense causing loss of junction control and barrier defects on the other. Large-scale analysis of gene expression profiles and identification of key pathways and master regulatory transcription factors will help dissect the role of nutritional and environmental factors as well as pharmacological intervention on mucosal homeostasis and disease, with potential applications for diagnosis and therapy.

Metabolic learning - intestine

References

• 1 Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome.  Lancet. 2005;  365 1415-1428
• 2 Kitano H, Oda K, Kimura T. et al. . Metabolic syndrome and robustness tradeoffs.  Diabetes. 2004;  53 Suppl 3 6-15
• 3 Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome.  Endocrinology. 2003;  144 5159-5165
• 4 Podolsky DK. Regulation of intestinal epithelial proliferation: a few answers, many questions.  Am J Physiol. 1993;  264 179-186
• 5 Clatworthy JP, Subramanian V. Stem cells and the regulation of proliferation, differentiation and patterning in the intestinal epithelium: emerging insights from gene expression patterns, transgenic and gene ablation studies.  Mech Dev. 2001;  101 3-9
• 6 Boudreau F, Rings EH, van Wering HM. et al. . Hepatocyte nuclear factor-1 alpha, GATA-4, and caudal related homeodomain protein Cdx2 interact functionally to modulate intestinal gene transcription. Implication for the developmental regulation of the sucrase-isomaltase gene.  J Biol Chem. 2002;  277 31909-31917
• 7 Hinoi T, Lucas PC, Kuick R. et al. . CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia.  Gastroenterology. 2002;  123 1565-1577
• 8 James R, Erler T, Kazenwadel J. Structure of the murine homeobox gene cdx-2. Expression in embryonic and adult intestinal epithelium.  J Biol Chem. 1994;  269 15229-15237
• 9 Silberg DG, Swain GP, Suh ER. et al. . Cdx1 and cdx2 expression during intestinal development.  Gastroenterology. 2000;  119 961-971
• 10 Mutoh H, Hakamata Y, Sato K. et al. . Conversion of gastric mucosa to intestinal metaplasia in Cdx2-expressing transgenic mice.  Biochem Biophys Res Commun. 2002;  294 470-479
• 11 Kim S, Domon-Dell C, Wang Q. et al. . PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3 K, PKB/Akt, and NF-kappaB-dependent pathway.  Gastroenterology. 2002;  123 1163-1178
• 12 Yuasa Y, Nagasaki H, Akiyama Y. et al. . Relationship between CDX2 gene methylation and dietary factors in gastric cancer patients.  Carcinogenesis. 2005;  26 193-200
• 13 Uesaka T, Kageyama N, Watanabe H. Identifying target genes regulated downstream of Cdx2 by microarray analysis.  J Mol Biol. 2004;  337 647-660
• 14 Grey VL, Garofalo C, Greenberg GR. et al. . The adaptation of the small intestine after resection in response to free fatty acids.  Am J Clin Nutr. 1984;  40 1235-1242
• 15 Rubin DC. Nutrient regulation of intestinal growth and adaptation: role of glucagon-like peptide 2 and the enteroendocrine cell.  Gastroenterology. 1999;  117 261-263
• 16 Chappell VL, Thompson MD, Jeschke MG. et al. . Effects of incremental starvation on gut mucosa.  Dig Dis Sci. 2003;  48 765-769
• 17 Langmann T, Moehle C, Mauerer R. et al. . Loss of detoxification in inflammatory bowel disease: Dysregulation of pregnane X receptor target genes.  Gastroenterology. 2004;  127 26-40
• 18 Kalogeris TJ, Rodriguez MD, Tso P. Control of synthesis and secretion of intestinal apolipoprotein A-IV by lipid.  J Nutr. 1997;  127 537-543
• 19 Ostos MA, Lopez-Miranda J, Ordovas JM. et al. . Dietary fat clearance is modulated by genetic variation in apolipoprotein A-IV gene locus.  J Lipid Res. 1998;  39 2493-2500
• 20 Ostos MA, Lopez-Miranda J, Marin C. et al. . The apolipoprotein A-IV-360His polymorphism determines the dietary fat clearance in normal subjects.  Atherosclerosis. 2000;  153 209-217
• 21 Qin X, Tso P. The role of apolipoprotein AIV on the control of food intake.  Curr. Drug Targets. 2005;  6 145-151
• 22 Dodson BD, Wang JL, Swietlicki EA. et al. . Analysis of cloned cDNAs differentially expressed in adapting remnant small intestine after partial resection.  Am J Physiol. 1996;  271 347-356
• 23 Vowinkel T, Mori M, Krieglstein CF. et al. . Apolipoprotein A-IV inhibits experimental colitis.  J Clin Invest. 2004;  114 260-269
• 24 Kramer W, Girbig F, Corsiero D. et al. . Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor Ezetimibe in the enterocyte brush border membrane.  J Biol Chem. 2004;  280 1306-1320 , Epub 2004 Oct 19
• 25 Montoya CA, Leterme P, Lalles JP. A protein-free diet alters small intestinal architecture and digestive enzyme activities in rats.  Reprod Nutr Dev. 2006;  46 49-56
• 26 Hanefeld M. The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus.  J. Diabetes Complications. 1998;  12 228-237
• 27 Chiasson JL, Josse RG, Gomis R. et al. . Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.  JAMA. 2003;  290 486-494
• 28 Paiva L, Binsack R, Machado UF. Chronic acarbose-feeding increases GLUT1 protein without changing intestinal glucose absorption function 1.  Eur J Pharmacol. 2002;  434 197-204

Correspondence